EUVIMEDEUVIMED entdecken
Crossref

A Comparative Study to Evaluate the Safety and Efficacy of Tablet Montelukast with Fexofenadine versus Tablet Montelukast with Levocetirizine in Patient of Allergic Rhinitis in Tertiary Care Centre

Preeti Sahani, Anil Kumar, Mahima Singh, Prem Narain Singh, Shilpa U. Vahika, Vahika Rizvi

International Journal of Current Pharmaceutical Review and Research · 30.06.2026 · 18 (06)

DOI: 10.25258/ijcpr.18.6.289 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Current Pharmaceutical Review and Research, online erschienen am 30.06.2026. Verfasst von Preeti Sahani und 5 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Allergic rhinitis is a common IgE-mediated inflammatory disorder of the nasal mucosa that impairs quality of life. Combination therapy with a leukotriene receptor antagonist and an antihistamine is widely used, but comparative data between different antihistamine partners remain limited. Material and Methods: In this prospective, randomized, parallel-group study, 277 patients with allergic rhinitis received either Montelukast plus Fexofenadine (Group A, n=139) or Montelukast plus Levocetirizine (Group B, n=138) for three months. TNSS, TOSS, RQLQ, VAS, serum IgE, and AEC were assessed at baseline, 15 days, 1, 2, and 3 months; adverse events were recorded throughout.

Results

Baseline demographic and clinical characteristics were comparable between groups (Table 1). Both groups showed progressive improvement in TNSS, TOSS, VAS, RQLQ, serum IgE, and AEC over follow-up, with no significant difference in the primary outcome (TNSS) at any time point (Table 2, Figure 1). Group A showed higher AEC at 1 and 3 months (p=0.047, p=0.039) and greater RQLQ improvement at 2 and 3 months (p=0.042, p=0.048) (Table 2, Figure 2). At study end, rhinorrhea control was better with Group B (p=0.026), while overall satisfaction was marginally higher with Group A (p=0.049) (Table 3). Both regimens were well tolerated, with mild, comparable rates of drowsiness, gastrointestinal symptoms, and other adverse events; no serious adverse events occurred (Table 4).

Conclusion

Montelukast–Fexofenadine and Montelukast–Levocetirizine combinations are equally effective and safe for allergic rhinitis, with treatment selection guided by individual symptom profile and tolerability.

Zitieren

APA

Sahani, P., Kumar, A., Singh, M., Singh, P. N., Vahika, S. U., & Rizvi, V. (2026). A Comparative Study to Evaluate the Safety and Efficacy of Tablet Montelukast with Fexofenadine versus Tablet Montelukast with Levocetirizine in Patient of Allergic Rhinitis in Tertiary Care Centre. International Journal of Current Pharmaceutical Review and Research, 18(06). https://doi.org/10.25258/ijcpr.18.6.289

Vancouver

Sahani P, Kumar A, Singh M, Singh PN, Vahika SU, Rizvi V. A Comparative Study to Evaluate the Safety and Efficacy of Tablet Montelukast with Fexofenadine versus Tablet Montelukast with Levocetirizine in Patient of Allergic Rhinitis in Tertiary Care Centre. International Journal of Current Pharmaceutical Review and Research. 2026;18(06). doi:10.25258/ijcpr.18.6.289

BibTeX
@article{Sahani2026,
  author = {Sahani, Preeti and Kumar, Anil and Singh, Mahima and Singh, Prem Narain and Vahika, Shilpa U. and Rizvi, Vahika},
  title = {A Comparative Study to Evaluate the Safety and Efficacy of Tablet Montelukast with Fexofenadine versus Tablet Montelukast with Levocetirizine in Patient of Allergic Rhinitis in Tertiary Care Centre},
  journal = {International Journal of Current Pharmaceutical Review and Research},
  year = {2026},
  volume = {18},
  number = {06},
  doi = {10.25258/ijcpr.18.6.289}
}
Kostenlos starten →